Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016 (2016), Article ID 2192853, 7 pages
http://dx.doi.org/10.1155/2016/2192853
Research Article

Discovery and Validation of Hypermethylated Markers for Colorectal Cancer

1Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China
2Bio-Bank of Department of General Surgery, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China

Received 31 March 2016; Revised 6 June 2016; Accepted 15 June 2016

Academic Editor: Monica Neagu

Copyright © 2016 Jiufeng Wei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Colorectal carcinoma (CRC) is one of the most prevalent malignant tumors worldwide. Screening and early diagnosis are critical for the clinical management of this disease. DNA methylation changes have been regarded as promising biomarkers for CRC diagnosis. Here, we map DNA methylation profiling on CRC in six CRCs and paired normal samples using a 450 K bead array. Further analysis confirms the methylation status of candidates in two data sets from the Gene Expression Omnibus. Receiver operating characteristic (ROC) curves are calculated to determine the diagnostic performances. We identify 1549 differentially methylated regions (DMRs) showing differences in methylation between CRC and normal tissue. Two genes (ADD2 and AKR1B1), related to the DMRs, are selected for further validation. ROC curves show that the areas under the curves of ADD2 and AKR1B1 are higher than that of SEPT9, which has been clinically used as a screening biomarker of CRC. Our data suggests that aberrant DNA methylation of ADD2 and AKR1B1 could be potential screening markers of CRC.